| 國家衛生研究院 |
2022-02-20 |
Hospital factors that predict intention of health care workers to leave their job during the COVID-19 pandemic
|
Chen, YC;Wu, HC;Kuo, FT;Koh, D;Guo, YLL;Shiao, JSC |
| 淡江大學 |
2022-02-21 |
Teaching introduction to French Philosophy to Taiwanese French learners: A holistic approach
|
馬朱麗, Marie-Julie Maitre |
| 淡江大學 |
2022-02-21 |
Multi-species, multi-country analysis reveals North Americans are willing to pay for transborder migratory species conservation
|
Thogmartin, Wayne E.;Haefele, Michelle A.;Diffendorfer, Jay E.;Semmens, Darius J.;Derbridge, Jonathan J.;Lien, Aaron;Huang, Ta-Ken;Laura, López-Hoffman |
| 國家衛生研究院 |
2022-02-21 |
Prenatal antioxidant-enriched and pro-oxidant-contained food, IL4 and IL13 pathway genes, and cord blood IgE
|
Chen, CH;Lee, YL;Wu, MH;Chen, PJ;Wei, TS;Tseng, CI;Chen, WJ |
| 國家衛生研究院 |
2022-02-21 |
Association between Intensity of low-density lipoprotein cholesterol reduction with statin-based therapies and secondary stroke prevention: A meta-analysis of randomized clinical trials
|
Lee, M;Cheng, CY;Wu, YL;Lee, JD;Hsu, CY;Ovbiagele, B |
| 元培科技大學 |
2022-02-21 |
寵物美容丙級技術士證照考試在元培 專業教室就是合格考場
|
元培醫事科技大學 |
| 國立成功大學 |
2022-02-21 |
乳癌婦女性生活相關經驗－性的超越：從控制到重建的過程
|
林玟華; Lin, Wen-Hua |
| 國立成功大學 |
2022-02-21 |
基於速度注意力之雙分支影片超解析度演算法
|
張珈偉; Zhang, Jia-Wei |
| 國立成功大學 |
2022-02-21 |
Effects of symmetry breaking of the structurally-disordered Hamiltonian ensembles on the anisotropic decoherence of qubits
|
Chen;Hong-Bin |
| 國立成功大學 |
2022-02-21 |
Indoor Dye-Sensitized Solar Cells with Efficiencies Surpassing 26% Using Polymeric Counter Electrodes
|
Venkatesan;Shanmuganathan;Lin;Wei-Hsun;Hsu;Tzu-Hsien;Teng;Hsisheng;Lee;Yuh-Lang |
| 國立交通大學 |
2022-02-21T00:24:23Z |
【科普軼聞】模擬人生的方法
|
林一平/交大講座教授 |
| 國立交通大學 |
2022-02-21T00:24:25Z |
【活動花絮】林盈達教授、曾新穆教授榮獲科技部傑出研究獎
|
林珮雯 |
| 國立交通大學 |
2022-02-21T00:24:25Z |
【活動花絮】資工系畢業生與在校生代表致詞
|
王柏盛/資工系學生 |
| 國立交通大學 |
2022-02-21T00:24:25Z |
【活動花絮】參與國際頂尖會議 開拓國際視野
|
林珮雯 |
| 國立交通大學 |
2022-02-21T00:24:25Z |
【活動花絮】KKday 創辦人 陳明明：機會是留給會爭取的人
|
高儷玲 |
| 國立交通大學 |
2022-02-21T00:24:26Z |
【活動花絮】系友活動錦集
|
郭明華 |
| 國立交通大學 |
2022-02-21T00:24:26Z |
【News】
|
Anonymous |
| 國立交通大學 |
2022-02-21T00:24:26Z |
【Dean's Message】Together, we are Greater.
|
陳志成 |
| 國立交通大學 |
2022-02-21T00:24:26Z |
【Donation】
|
Anonymous |
| 國立交通大學 |
2022-02-21T00:24:26Z |
【活動花絮】善用科技：不畏懼疫情，資工英語圓桌推出遠距教學課
|
劉美君 |
| 國立交通大學 |
2022-02-21T00:24:26Z |
【Highlights】Education Innovation in Computer Science & Engineering at NCTU
|
林珮雯 |
| 國立交通大學 |
2022-02-21T00:24:26Z |
【Activities】XR Interdisciplinary Project Can Make Your Imagination Come True
|
林珮雯 |
| 國立交通大學 |
2022-02-21T00:24:27Z |
【Industry Collaboration Project】AI System Benchmarking and Tuning Lab: Accelerate the Pervasive Applications on Artificial Intelligence Technology among Industries
|
陳添福/資工系教授; 連慶/資科工所碩士生 |
| 國立交通大學 |
2022-02-21T00:24:27Z |
【資訊系友】趙書華學姐：互相成為別人的貴人
|
高儷玲 |
| 國立交通大學 |
2022-02-21T00:24:27Z |
【教師專訪】黃敬群教授：學無止境，勇於創新
|
高儷玲 |
| 國立交通大學 |
2022-02-21T00:24:27Z |
【資訊系友】蔡祈岩學長：正面的態度讓你哪裡都是舒適圈
|
高儷玲 |
| 國立交通大學 |
2022-02-21T00:24:27Z |
【科普軼聞】從水流星到洲際飛彈導航科技發展史
|
林一平/交大講座教授 |
| 國立交通大學 |
2022-02-21T00:24:27Z |
【Industry Collaboration Project】NCTU: The First-open Source 5G Core Network Launches
|
高儷玲 |
| 臺大學術典藏 |
2022-02-21T02:04:29Z |
High prevalence of APOA1/C3/A4/A5 alterations in luminal breast cancers among young women in East Asia
|
Lin C.-H.; Huang R.Y.-J.; Lu T.-P.; Kuo K.-T.; Lo K.-Y.; Chen C.-H.; Chen I.-C.; Lu Y.-S.; Chuang E.Y.; Thiery J.P.; Huang C.-S.; ANN-LII CHENG |
| 臺大學術典藏 |
2022-02-21T02:04:31Z |
Contribution of nuclear BCL10 expression to tumor progression and poor prognosis of advanced and/or metastatic pancreatic ductal adenocarcinoma by activating NF-�eB-related signaling
|
Kuo S.-H.; Yang S.-H.; Wei M.-F.; Lee H.-W.; Tien Y.-W.; ANN-LII CHENG; Yeh K.-H. |
| 臺大學術典藏 |
2022-02-21T02:04:31Z |
APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy
|
Lau G.; Yu M.-L.; Wong G.; Thompson A.; Ghazinian H.; Hou J.-L.; Piratvisuth T.; Jia J.-D.; Mizokami M.; Cheng G.; Chen G.-F.; Liu Z.-W.; Baatarkhuu O.; ANN-LII CHENG; Ng W.L.; Lau P.; Mok T.; Chang J.-M.; Hamid S.; Dokmeci A.K.; Gani R.A.; Payawal D.A.; Chow P.; Park J.-W.; Strasser S.I.; Mohamed R.; Win K.M.; Tawesak T.; Sarin S.K.; Omata M. |
| 臺大學術典藏 |
2022-02-21T02:04:32Z |
Anti-HER2 antibody prolongs overall survival disproportionally more than progression-free survival in HER2-Positive metastatic breast cancer patients
|
Chen I.-C.; Hu F.-C.; Lin C.-H.; Huang S.-M.; Chang D.-Y.; ANN-LII CHENG; Lu Y.-S. |
| 臺大學術典藏 |
2022-02-21T02:04:32Z |
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma
|
Greten T.F.; Abou-Alfa G.K.; ANN-LII CHENG; Duffy A.G.; El-Khoueiry A.B.; Finn R.S.; Galle P.R.; Goyal L.; He A.R.; Kaseb A.O.; Kelley R.K.; Lencioni R.; Lujambio A.; Mabry Hrones D.; Pinato D.J.; Sangro B.; Troisi R.I.; Wilson Woods A.; Yau T.; Zhu A.X.; Melero I. |
| 臺大學術典藏 |
2022-02-21T02:04:32Z |
Pharmacodynamic biomarkers predictive of survival benefit with lenvatinib in unresectable hepatocellular carcinoma: From the phase III REFLECT study
|
Finn R.S.; Kudo M.; ANN-LII CHENG; Wyrwicz L.; Ngan R.K.C.; Blanc J.-F.; Baron A.D.; Vogel A.; Ikeda M.; Piscaglia F.; Han K.-H.; Qin S.; Minoshima Y.; Kanekiyo M.; Ren M.; Dairiki R.; Tamai T.; Dutcus C.E.; Ikezawa H.; Funahashi Y.; Evans T.R.J. |
| 臺大學術典藏 |
2022-02-21T02:04:33Z |
Dynamic contrast-enhanced and intravoxel incoherent motion mri biomarkers are correlated to survival outcome in advanced hepatocellular carcinoma
|
Chen B.-B.; Shao Y.-Y.; Lin Z.-Z.; Hsu C.-H.; ANN-LII CHENG; Hsu C.; Liang P.-C.; Shih T.T.-F. |
| 臺大學術典藏 |
2022-02-21T02:04:33Z |
Evolution of systemic treatment for advanced hepatocellular carcinoma
|
Wu T.-C.; Shen Y.-C.; ANN-LII CHENG |
| 臺大學術典藏 |
2022-02-21T02:04:33Z |
Association between risk factors, molecular features and CpG island methylator phenotype colorectal cancer among different age groups in a Taiwanese cohort
|
Chen K.-H.; Lin L.-I.; Yuan C.-T.; Tseng L.-H.; Chao Y.-L.; Liang Y.-H.; Liang J.-T.; Lin B.-R.; ANN-LII CHENG; Yeh K.-H. |
| 臺大學術典藏 |
2022-02-21T02:04:34Z |
Eg5 as a prognostic biomarker and potential therapeutic target for hepatocellular carcinoma
|
Shao Y.-Y.; Sun N.-Y.; Jeng Y.-M.; Wu Y.-M.; Hsu C.; Hsu C.-H.; Hsu H.-C.; ANN-LII CHENG; Lin Z.-Z. |
| 臺大學術典藏 |
2022-02-21T02:04:34Z |
Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial
|
Galle P.R.; Finn R.S.; Qin S.; Ikeda M.; Zhu A.X.; Kim T.-Y.; Kudo M.; Breder V.; Merle P.; Kaseb A.; Li D.; Mulla S.; Verret W.; Xu D.-Z.; Hernandez S.; Ding B.; Liu J.; Huang C.; Lim H.Y.; ANN-LII CHENG; Ducreux M. |
| 臺大學術典藏 |
2022-02-21T02:04:35Z |
Exploring Markers of Exhausted CD8 T Cells to Predict Response to Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma
|
Hsu C.-L.; Ou D.-L.; Bai L.-Y.; Chen C.-W.; Lin L.; Huang S.-F.; ANN-LII CHENG; Jeng Y.-M.; Hsu C. |
| 臺大學術典藏 |
2022-02-21T02:04:35Z |
Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study
|
Qin S.; Ren Z.; Feng Y.-H.; Yau T.; Wang B.; Zhao H.; Bai Y.; Gu S.; Li L.; Hernandez S.; Xu D.-Z.; Mulla S.; Wang Y.; Shao H.; ANN-LII CHENG |
| 臺大學術典藏 |
2022-02-21T02:04:35Z |
Safety and efficacy of lenvatinib by starting dose based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT
|
Okusaka T.; Ikeda K.; Kudo M.; Finn R.; Qin S.; Han K.-H.; ANN-LII CHENG; Piscaglia F.; Kobayashi M.; Sung M.; Chen M.; Wyrwicz L.; Yoon J.-H.; Ren Z.; Mody K.; Dutcus C.; Tamai T.; Ren M.; Hayato S.; Kumada H. |
| 臺大學術典藏 |
2022-02-21T02:04:35Z |
Pembrolizumab as second-line therapy for advanced hepatocellular carcinoma: A subgroup analysis of asian patients in the phase 3 KEYNOTE-240 trial
|
Kudo M.; Lim H.Y.; ANN-LII CHENG; Chao Y.; Yau T.; Ogasawara S.; Kurosaki M.; Morimoto N.; Ohkawa K.; Yamashita T.; Lee K.-H.; Chen E.; Siegel A.B.; Ryoo B.-Y. |
| 臺大學術典藏 |
2022-02-21T02:04:36Z |
Regorafenib enhances antitumor immunity via inhibition of p38 kinase/Creb1/Klf4 axis in tumor-associated macrophages
|
Ou D.-L.; Chen C.-W.; Hsu C.-L.; Chung C.-H.; Feng Z.-R.; Lee B.-S.; ANN-LII CHENG; Yang M.-H.; Hsu C. |
| 臺大學術典藏 |
2022-02-21T02:04:36Z |
Prognostic value of PD-L1 expression on immune cells or tumor cells for locally advanced esophageal squamous cell carcinoma in patients treated with neoadjuvant chemoradiotherapy
|
Huang T.-C.; Liang C.-W.; Li Y.-I.; Guo J.-C.; Lin C.-C.; Chen Y.-J.; ANN-LII CHENG; Hsu C.-H. |
| 臺大學術典藏 |
2022-02-21T02:51:54Z |
Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: Results from a phase I/II open-label, multicenter study
|
Zucali P.A.; Lin C.-C.; Carthon B.C.; Bauer T.M.; Tucci M.; Italiano A.; Iacovelli R.; Su W.-C.; Massard C.; Saleh M.; Daniele G.; Greystoke A.; Gutierrez M.; Pant S.; YING-CHUN SHEN; Perrino M.; Meng R.; Abbadessa G.; Lee H.; Dong Y.; Chiron M.; Wang R.; Loumagne L.; L?pine L.; De Bono J. |
| 臺大學術典藏 |
2022-02-21T02:51:54Z |
Limited predictive or prognostic role of tumor-infiltrating tissue-resident memory cd8 t cells in patients with hepatocellular carcinoma receiving immunotherapy
|
YING-CHUN SHEN; Yeh C.-P.; Jeng Y.-M.; Hsu C.; Hsu C.-H.; Lin Z.-Z.; Shao Y.-Y.; Lu L.-C.; Liu T.-H.; Chen C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2022-02-21T02:51:55Z |
Evolution of systemic treatment for advanced hepatocellular carcinoma
|
Wu T.-C.; YING-CHUN SHEN; Cheng A.-L. |
| 臺大學術典藏 |
2022-02-21T03:52:30Z |
Serial Plasma Cell-Free Circulating Tumor DNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome in EGFR T790M�VPositive NSCLC
|
Liao B.-C.; Hsu W.-H.; JIH-HSIANG LEE; Yang C.-Y.; Tsai T.-H.; Liao W.-Y.; Ho C.-C.; Lin C.-C.; Shih J.-Y.; Yu C.-J.; Soo R.A.; Yang J.C.-H. |
| 臺大學術典藏 |
2022-02-21T03:52:31Z |
Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours
|
de Bono J.; Lin C.-C.; Chen L.-T.; Corral J.; Michalarea V.; Rihawi K.; Ong M.; JIH-HSIANG LEE; Hsu C.-H.; Yang J.C.-H.; Shiah H.-S.; Yen C.-J.; Anthoney A.; Jove M.; Buschke S.; Fuertig R.; Schmid U.; Goeldner R.-G.; Strelkowa N.; Huang D.C.-L.; Bogenrieder T.; Twelves C.; Cheng A.-L. |
